Abstract
Neuroblastic tumors (NBs) show diverse clinical presentation ranging from a regression, through delayed or arrested maturation, to the metastatic spread. The different biological behavior of NBs seems to be determined by the molecular mechanisms associated with neural crest development. HER receptors family which modulates neurogenesis, is involved in genesis and progression of several types of cancer. HER receptors are commonly expressed in NB tumors and it seems that HER family members play an interrelated and complex role in their biology. It is suggested that HERs are related to the neuroblastic cell differentiation and Schwannian stroma development. Moreover, HER expression is considered a potential prognostic factor. Because new treatment options are still warranted in high risk NBs, HER receptors become an evolving target for novel therapeutic approaches such as tyrosine kinase inhibitors or specific antibodies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Baselga J, Swain S (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463–475
Casalini P, Iorio M, Galmozzi E, Menard S (2004) Role of HER receptors family in development and differentiation. J Cell Physiol 200:343–350
Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505–516
Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay K (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J Clin Oncol 27:289–297
Evangelopoulos M, Weis J, Kruttgen A (2009) Mevastatin-induced neurite outgrowth of neuroblastoma cells via activation of EGFR. J Neurosci Res 87:2138–2144
Fong A, Park J (2009) High-risk neuroblastoma: a therapy in evolution. Pediatr Hematol Oncol 26:539–548
Gambini C, Sementa AR, Boni L, Marino CE, Corce M, Negri F, Pistoia V, Ferrini S, Corrias MV (2003) Expression of HER2/neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression. Cancer Immunol Immunother 52:116–120
Gilbertson RJ (2005) ERBB2 in pediatric cancer: innocent until proven guilty. Oncologist 10:508–517
Goji J, Nakamura H, Ito H, Mabuchi O, Hashimoto K, Sano K (1995) Expression of c-ErbB2 in human neuroblastoma tissues, adrenal medulla adjacent to tumor, and developing mouse neural crest cells. Am J Pathol 146:660–672
Gullick WJ (2003) c-erbB-4/HER4: friend or foe? J Pathol 200:279–281
Hirsch F, Varella-Garcia M, Cappuzzo F (2009) Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28:S32–S37
Ho R, Minturn J, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans A, Brodeur G (2005) Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 65:9868–9875
Izycka-Swieszewska E, Brzeskwiniewicz M, Wozniak A, Drozynska E, Grajkowska W, Perek D, Balcerska A, Klepacka T, Limon J (2010a) EGFR, PI3KCA and PTEN genes status and their protein product expression in neuroblastic tumors. Folia Neuropathol 48:238–245
Izycka-Swieszewska E, Wozniak A, Kot J, Grajkowska W, Balcerska A, Perek D, Dembowska-Baginska B, Klepacka T, Drozynska E (2010b) Prognostic significance of HER2 expression in neuroblastic tumors. Mod Pathol 23:1261–1268
Izycka-Swieszewska E, Wozniak A, Drozynska E, Kot J, Grajkowska W, Klepacka T, Perek D, Koltan S, Bien E, Limon J (2011) Expression and prognostic significance of HER family receptors in neuroblastic tumors. Clin Exp Metastasis 28:271–282
Jakacki R, Hamilton M, Gilbertson R, Blaney S, Terask J, Krailo M, Ingle A, Voss S, Dancey J, Adamson P (2008) Pediatric phase I and pharmacokinetic study of Erlotinib followed by the combination of Erlotinib and Temozolomid: a children’s oncology group phase I consortium study. J Clin Oncol 26:4921–4927
Junttila T, Sundvall M, Maatta J, Elenius K (2000) ErbB4 and its isoforms. Selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med 10:304–310
Layfield L, Thompson K, Dodge R, Kerns B (1995) Prognostic indicators for neuroblastoma: stage, grade, DNA ploidy, MIB-1-proliferation index, p53, HER-2/neu and EGFR- a survival study. J Surg Oncol 59:21–27
Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B, Harris P, Haserlat S, Supko J, Haluska F, Louis D, Christiani D, Settleman J, Haber D (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139
Maris J, Hogarty M, Bagatell R, Cohn S (2007) Neuroblastoma. Lancet 369:2106–2120
Michaelis M, Bliss J, Arnold S, Hinsch N, Rothweiler F, Deubzer H, Witt O, Langer K, Doerr H, Wels W, Cinatl J (2008) Cisplatin-resistant neuroblastoma cells express enhanced levels of EGFR and are sensitive to treatment with EGFR-specific toxins. Clin Cancer Res 14:6531–6537
Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469–6487
Morris J, Lin W, Hauser C, Matchuk Y, Getman D, Lee K (1999) Rescue of the cardiac defect in ErbB2 mutant mice reveals essential roles of ErbB2 in peripheral nervous system development. Neuron 23:273–283
Moscatello D, Holgado-Madruga M, Godwin A, Ramirez G, Gunn G, Zoltick P, Biegel J, Hayes R, Wong A (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536–5539
Nakagawara A (2004) Neural crest development and neuroblastoma: the genetic and biological link. Prog Brain Res 146:233–242
Richards KN, Zweidler-McKay PA, Van Roy N, Speleman F, Trevino J, Zage P, Hughes D (2010) Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer 116:3233–3243
Rogers S, Box C, Chambers P, Barbachano Y, Nutting C, Rhys-Evans P, Workman P, Harrington K, Eccles S (2009) Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J Pathol 218:122–130
Rossler J, Odenthal E, Geoerger B, Gerstenmeyer A, Lagodny J, Niemeyer C, Vassal G (2009) EGFR inhibition using Gefitinib is not active in neuroblastoma cell lines. Anticancer Res 29:1327–1334
Shimada H, Ambros I, Dehner L, Hata J, Joshi V, Roald B, Stram D, Gerbing R, Lukens J, Matthay K, Castleberry R (1999) The international neuroblastoma pathology classification (the Shimada system). Cancer 86:364–372
Tamura S, Hosoi H, Kuwahara Y, Kikuchi K, Otabe O, Izumi M, Tsuchiya K, Iehara T, Gotoh T, Sugimoto T (2007) Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochem Biophys Res Commun 358:226–232
Vermuelen J, De Preter K, Mestdagh P, Laureys G, Speleman F, Vandensompele J (2010) Predicting outcomes for children with neuroblastoma. Discov Med 10:29–36
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Izycka-Swieszewska, E., Wozniak, A. (2012). Neuroblastic Tumors – Status and Role of HER Family Receptors. In: Hayat, M. (eds) Pediatric Cancer, Volume 2. Pediatric Cancer, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2957-5_9
Download citation
DOI: https://doi.org/10.1007/978-94-007-2957-5_9
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-2956-8
Online ISBN: 978-94-007-2957-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)